New evidence demonstrates the potential of Prevo-Check® and tumour marker DRH1 for early detection of HPV-induced diseases

New evidence demonstrates the potential of Prevo-Check® and tumour marker DRH1 for early detection of HPV-induced diseases

Our product Prevo-Check®, a patented test for the detection of HPV16-induced tumours, is the focus of two studies to be presented at the international HPV (human papilloma virus) congress EUROGIN on December 4-7.

In a study conducted at the University of Graz, Dr. Weiland and colleagues discovered that Prevo-Check® is a rapid test for identifying patients with HPV16-induced oropharynx carcinoma, with a sensitivity of 95%. Furthermore, the tumour marker DRH1 could be used to monitor patient outcomes during and after cancer treatment. To learn more, see abstract #0669: “DRH1 – Evaluating a blood-based marker for HPV16-induced tumors”.

A further study conducted by Dr. Skaletz-Rorowski and Prof. Dr. med. Brockmeyer from the Center for Sexual Health at the University of Bochum evaluated the use of Prevo-Check® in the early detection of anal carcinoma in patients with HIV. This evidence will be presented as part of the session ‘Free Communications/Anal Neoplasia’, scheduled for Friday 6 December 10:00–11:30.  To learn more, see abstract #0366: “A blood-based tumor marker for the early detection and monitoring of HPV-induced anal cancer in HIV-patients”.

Abviris is excited that a growing body of evidence demonstrates the potential of Prevo-Check® for early detection of HPV-induced cancers. We would be delighted to collaborate with scientists, clinicians and commercial partners wishing to join our mission to improve patient outcomes in oncology.

Leave a reply

Your email address will not be published. Required fields are marked *

20 + thirteen =